Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22
- PMID: 12960212
- PMCID: PMC1735578
- DOI: 10.1136/jmg.40.9.671
Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22
Abstract
Background: Lafora disease is a progressive myoclonus epilepsy with polyglucosan accumulations and a peculiar neurodegeneration with generalised organellar disintegration. It causes severe seizures, leading to dementia and eventually death in early adulthood.
Methods: One Lafora disease gene, EPM2A, has been identified on chromosome 6q24. Locus heterogeneity led us to search for a second gene using a genome wide linkage scan in French-Canadian families.
Results: We mapped a second Lafora disease locus, EPM2B, to a 2.2 Mb region at 6p22, a region known to code for several proteins, including kinesins. Kinesins are microtubule dependent motor proteins that are involved in transporting cellular components. In neurones, they play a major role in axonal and dendritic transport.
Conclusion: Analysis of the present locus in other non-EPM2A families will reveal whether there is further locus heterogeneity. Identification of the disease gene will be of major importance towards our understanding of the pathogenesis of Lafora disease.
Similar articles
-
Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus.Neurology. 2004 Aug 10;63(3):565-7. doi: 10.1212/01.wnl.0000133215.65836.03. Neurology. 2004. PMID: 15304597
-
Early-onset Lafora body disease.Brain. 2012 Sep;135(Pt 9):2684-98. doi: 10.1093/brain/aws205. Brain. 2012. PMID: 22961547 Free PMC article.
-
Lafora disease due to EPM2B mutations: a clinical and genetic study.Neurology. 2005 Mar 22;64(6):982-6. doi: 10.1212/01.WNL.0000154519.10805.F7. Neurology. 2005. PMID: 15781812
-
[Lafora's disease (EPM2)].Rev Neurol (Paris). 2007 Jan;163(1):47-53. doi: 10.1016/s0035-3787(07)90354-9. Rev Neurol (Paris). 2007. PMID: 17304172 Review. French.
-
[Efficacy of zonisamide in Lafora's disease case and brief review of its use in progressive myoclonic epilepsy].Rev Neurol. 2022 Sep 16;75(6):159-163. doi: 10.33588/rn.7506.2021397. Rev Neurol. 2022. PMID: 36098450 Free PMC article. Review. Spanish.
Cited by
-
Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy.J Hum Genet. 2006;51(1):1-8. doi: 10.1007/s10038-005-0321-1. Epub 2005 Nov 26. J Hum Genet. 2006. PMID: 16311711 Review.
-
Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA).Epilepsy Behav Case Rep. 2017 May 26;8:44-46. doi: 10.1016/j.ebcr.2017.05.004. eCollection 2017. Epilepsy Behav Case Rep. 2017. PMID: 28856097 Free PMC article.
-
Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population.J Hum Genet. 2005;50(7):347-352. doi: 10.1007/s10038-005-0263-7. Epub 2005 Jul 15. J Hum Genet. 2005. PMID: 16021330
-
Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan.Int J Mol Sci. 2017 Aug 11;18(8):1743. doi: 10.3390/ijms18081743. Int J Mol Sci. 2017. PMID: 28800070 Free PMC article. Review.
-
A Novel Mutation in Lafora Disease and Update on Pathophysiology and Future Treatments.Child Neurol Open. 2022 Oct 5;9:2329048X221126361. doi: 10.1177/2329048X221126361. eCollection 2022 Jan-Dec. Child Neurol Open. 2022. PMID: 36211619 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous